Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

Crafter,Claire; Vincent,John  P.; Tang,Eric; Dudley,Phillippa; James,Neil  H.; Klinowska,Teresa; Davies,Barry  R.

doi:10.3892/ijo.2015.3062

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

Authors:
- Claire Crafter
- John P. Vincent
- Eric Tang
- Phillippa Dudley
- Neil H. James
- Teresa Klinowska
- Barry R. Davies
View Affiliations

Affiliations: Oncology iMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK
Published online on: June 22, 2015 https://doi.org/10.3892/ijo.2015.3062
Pages: 446-454
Copyright: © Crafter et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling network is frequently de-regulated in breast cancer and has been shown to mediate resistance to anti-HER2 agents. Whilst constitutive activation of this pathway is emerging as a marker of sensitivity to various PI3K pathway inhibitors, activity of these agents in the clinic may be limited by the presence of feedback loops, leading to reactivation of receptor tyrosine kinases, such as HER2/HER3. To determine whether inhibition of HER2 could increase the efficacy of AZD5363, a novel AKT inhibitor, a panel of breast cancer cells was dosed with AZD5363 in combination with AZD8931, an inhibitor of EGFR/HER2/HER3 signalling. We show that the combined treatment resulted in synergistic growth inhibition and enhanced cell death, specifically in the HER2-amplified cell lines. Investigation of the mechanism by western blot analysis revealed that the addition of AZD8931 prevented the induction of HER2/HER3 phosphorylation induced by AZD5363 and resulted in concomitant inhibition of both the PI3K/AKT/mTOR and ERK signalling pathways and induction of apoptosis. Using the HCC1954 xenograft model, which is resistant to trastuzumab, we show that the combination of AZD5363 and AZD8931 is more efficacious than either agent alone, resulting in profound tumour regressions. We conclude that the activity of AZD5363 in HER2-amplified breast cancer cells is enhanced by the addition of AZD8931 and that dual targeting of AKT and EGFR/HER2/HER3 signalling is an attractive treatment option to be explored in the clinic.

View Figures

View References

1	Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464. 2005. View Article : Google Scholar : PubMed/NCBI
2	Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
3	Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
4	Serra V, Markman B, Scaltriti M, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI
5	Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL and Powis G: Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 69:143–150. 2009. View Article : Google Scholar : PubMed/NCBI
6	Di Nicolantonio F, Arena S, Tabernero J, et al: Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 120:2858–2866. 2010. View Article : Google Scholar : PubMed/NCBI
7	Davies BR, Greenwood H, Dudley P, et al: Preclinical pharmacology of AZD5363, an inhibitor of AKT: Pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 11:873–887. 2012. View Article : Google Scholar : PubMed/NCBI
8	Janku F, Tsimberidou AM, Garrido-Laguna I, et al: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 10:558–565. 2011. View Article : Google Scholar : PubMed/NCBI
9	Janku F, Hong DS, Fu S, et al: Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 6:377–387. 2014. View Article : Google Scholar : PubMed/NCBI
10	Bucheit AD and Davies MA: Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol. 87:381–389. 2014. View Article : Google Scholar
11	Tartarone A, Lazzari C, Lerose R, Conteduca V, Improta G, Zupa A, Bulotta A, Aieta M and Gregorc V: Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer. 81:328–336. 2013. View Article : Google Scholar : PubMed/NCBI
12	Chandarlapaty S: Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov. 2:311–319. 2012. View Article : Google Scholar : PubMed/NCBI
13	Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, Olefsky JM and Kobayashi M: A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 14:783–794. 2000. View Article : Google Scholar : PubMed/NCBI
14	O’Reilly KE, Rojo F, She QB, et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar
15	Yu Y, Yoon SO, Poulogiannis G, et al: Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 332:1322–1326. 2011. View Article : Google Scholar : PubMed/NCBI
16	Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J and Rosen N: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 19:58–71. 2011. View Article : Google Scholar : PubMed/NCBI
17	Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB and Brugge JS: Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 21:227–239. 2012. View Article : Google Scholar : PubMed/NCBI
18	Fox EM, Kuba MG, Miller TW, Davies BR and Arteaga CL: Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res. 15:R552013. View Article : Google Scholar : PubMed/NCBI
19	Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6:117–127. 2004. View Article : Google Scholar : PubMed/NCBI
20	Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 12:395–402. 2007. View Article : Google Scholar : PubMed/NCBI
21	Eichhorn PJ, Gili M, Scaltriti M, et al: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 68:9221–9230. 2008. View Article : Google Scholar : PubMed/NCBI
22	Chandarlapaty S, Sakr RA, Giri D, et al: Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res. 18:6784–6791. 2012. View Article : Google Scholar : PubMed/NCBI
23	Miller TW, Forbes JT, Shah C, et al: Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res. 15:7266–7276. 2009. View Article : Google Scholar : PubMed/NCBI
24	Serra V, Scaltriti M, Prudkin L, et al: PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 30:2547–2557. 2011. View Article : Google Scholar : PubMed/NCBI
25	Chakrabarty A, Sánchez V, Kuba MG, Rinehart C and Arteaga CL: Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA. 109:2718–2723. 2012. View Article : Google Scholar :
26	García-García C, Ibrahim YH, Serra V, et al: Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res. 18:2603–2612. 2012. View Article : Google Scholar : PubMed/NCBI
27	Hickinson DM, Klinowska T, Speake G, et al: AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: A unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res. 16:1159–1169. 2010. View Article : Google Scholar : PubMed/NCBI
28	Lehár J, Krueger AS, Avery W, et al: Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 27:659–666. 2009. View Article : Google Scholar : PubMed/NCBI
29	Rickles RJ, Tam WF, Giordano TP III, et al: Adenosine A2A and beta-2 adrenergic receptor agonists: Novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. Mol Cancer Ther. 11:1432–1442. 2012. View Article : Google Scholar : PubMed/NCBI
30	Garnett MJ, Edelman EJ, Heidorn SJ, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 483:570–575. 2012. View Article : Google Scholar : PubMed/NCBI
31	Elvin P, Palmer A, Womack C, et al: Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors. J Clin Oncol. 32(Suppl 5): 25412014.
32	Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R and Shokat KM: Inhibitor hijacking of Akt activation. Nat Chem Biol. 5:484–493. 2009. View Article : Google Scholar : PubMed/NCBI
33	Rexer BN and Arteaga CL: Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: Mechanisms and clinical implications. Crit Rev Oncog. 17:1–16. 2012. View Article : Google Scholar : PubMed/NCBI